Advanced Oncotherapy Plc Delivering on plan

Hardman & Co ReportAdvanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel proton-based radiotherapy system, based on a technology originally developed and tested at the world renowned CERN. Management has proven its capability of following tight timelines and remains on schedule to deliver the first LIGHT system in 2017. Progress on Planning Permission for its Harley Street site remains very much on track for 2016, while planning for the Pebble Mill site is taking shape, and financing for this development is now in place. Having entered in an industrialisation agreement with Thales, AVO announced the agreement for a £24m loan from Metric Capital.

 
► Strategy: To develop a compact and modular proton therapy system at an affordable price for the payor, financially attractive to the operator, whilst generating superior patient outcomes. AVO benefits from the technology know-how developed by ADAM and relies on a base of world-class suppliers.

► LIGHT development: AVO’s manufacturing plan has been demonstrated through the successful achievement of key milestones on time and as stated at the investor day back in 4Q 2014. AVO has also signed an industrialisation agreement with Thales which strengthens its execution capabilities.

► Financing: AVO has secured a £24m financing facility to support the installation of LIGHT in Harley Street. This loan facility will be in two tranches and will carry a cash coupon of 4.0% and 8.5% PIK over a maximum of 5 yrs. In addition, Metric has been granted 580,000 warrants at 400p per share.

► Planning permissions: The planning application for the Harley Street facility was submitted in June and is expected to be approved during 2016. In parallel, the company is working also on the planning process for its second site in the UK, in Pebble Mill, Birmingham.

► Valuation: With two system sales in China, a potential order book of 12 systems ($480m+) and the capacity to produce up to 30 systems per annum, operational momentum is building.

► Investment summary: Advanced Oncotherapy Plc is entering a market on the cusp of a steepening adoption curve, not least in China, with a proton therapy solution that is unique with respect to its competitors and addresses the needs of all key stakeholders.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Hardman & Co

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked